Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Di Napoli

Showing results (11-20 of 143) with videos related to

Pageof 15
Sort By:
Circulation|August 10, 2005
C-reactive protein and cerebral small-vessel disease: an opportunity to reassess small-vessel disease physiopathology?Mario Di Napoli, Francesca Papa
Current Opinion in Investigational Drugs (London, England : 2000)|October 30, 2003
NCX-4016 NicOxMario Di Napoli, Francesca Papa
Stroke|July 10, 2002
Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patientsMario Di Napoli, Francesca Papa,
Current Opinion in Investigational Drugs (London, England : 2000)|May 9, 2003
MLN-519. Millennium/PAIONMario Di Napoli, Francesca Papa
Current Opinion in Investigational Drugs (London, England : 2000)|July 28, 2005
The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitorsMario Di Napoli, BethAnn McLaughlin
Stroke|November 8, 2003
Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic strokeMario Di Napoli, Francesca Papa
Archives of Neurology|January 21, 2004
POEMS syndrome, fibrinogen, and ischemic stroke: a critical point of viewMario Di Napoli, Arsen Arakelyan
Stroke|May 1, 2004
Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapyCezary Wojcik, Mario Di Napoli
Idrugs : the Investigational Drugs Journal|January 15, 2005
M-40403 Metaphore PharmaceuticalsMario Di Napoli, Francesca Papa
Expert Review of Neurotherapeutics|April 28, 2005
Clinical application of C-reactive protein in stroke prevention: bright and dark sides of the moonMario Di Napoli, Francesca Papa
Pageof 15

Showing results (11-20 of 143) with videos related to

Sort By:
Pageof 15
Circulation|August 10, 2005
C-reactive protein and cerebral small-vessel disease: an opportunity to reassess small-vessel disease physiopathology?Mario Di Napoli, Francesca Papa
Current Opinion in Investigational Drugs (London, England : 2000)|October 30, 2003
NCX-4016 NicOxMario Di Napoli, Francesca Papa
Stroke|July 10, 2002
Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patientsMario Di Napoli, Francesca Papa,
Current Opinion in Investigational Drugs (London, England : 2000)|May 9, 2003
MLN-519. Millennium/PAIONMario Di Napoli, Francesca Papa
Current Opinion in Investigational Drugs (London, England : 2000)|July 28, 2005
The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitorsMario Di Napoli, BethAnn McLaughlin
Stroke|November 8, 2003
Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic strokeMario Di Napoli, Francesca Papa
Archives of Neurology|January 21, 2004
POEMS syndrome, fibrinogen, and ischemic stroke: a critical point of viewMario Di Napoli, Arsen Arakelyan
Stroke|May 1, 2004
Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapyCezary Wojcik, Mario Di Napoli
Idrugs : the Investigational Drugs Journal|January 15, 2005
M-40403 Metaphore PharmaceuticalsMario Di Napoli, Francesca Papa
Expert Review of Neurotherapeutics|April 28, 2005
Clinical application of C-reactive protein in stroke prevention: bright and dark sides of the moonMario Di Napoli, Francesca Papa
Pageof 15